Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  La Jolla Pharmaceutical Company    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

LA JOLLA PHARMACEUTICAL COMPANY : REVERSE SPLIT: 1 for 50

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2014 CEST
REVERSE SPLIT: 1 for 50


© Factset 2014
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LA JOLLA PHARMACEUTICAL CO
06/01 LA JOLLA PHARMACEUTICAL : Results of ATHOS-3 Phase 3 Study of LJPC-501 Published..
05/23 LA JOLLA PHARMACEUTICAL : posts mixed bag of phase 3 data, raising hopes of FDA ..
05/22 LA JOLLA PHARMACEUTICAL COMPANY (NAS : LJPC) Files An 8-K Other Events
05/22 LA JOLLA PHARMACEUTICAL CO : Other Events, Financial Statements and Exhibits (fo..
05/22 LA JOLLA PHARMACEUTICAL : Results of ATHOS‑3 Phase 3 Study of LJPC-501 Pub..
05/21 LA JOLLA PHARMACEUTICAL : Results of ATHOS-3 Phase 3 Study of LJPC-501 Published..
05/18 LA JOLLA PHARMACEUTICAL COMPANY (NAS : LJPC) Files An 8-K Other Events
05/18 LA JOLLA PHARMACEUTICAL CO : Other Events (form 8-K)
05/01 LA JOLLA PHARMACEUTICAL COMPANY (NAS : LJPC) Files An 8-K Results of Operations ..
05/01 LA JOLLA PHARMACEUTICAL CO : Results of Operations and Financial Condition, Fina..
More news
Financials ($)
Sales 2017 0,27 M
EBIT 2017 -93,6 M
Net income 2017 -102 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 2 741x
Capi. / Sales 2018 19,7x
Capitalization 741 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 55,4 $
Spread / Average Target 65%
EPS Revisions
Managers
NameTitle
George Francis Tidmarsh President, CEO, Secretary & Director
Kevin C. Tang Chairman
Jennifer Carver Senior Vice President-Operations
Dennis M. Mulroy Chief Financial & Accounting Officer
Lakhmir S. Chawla Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
LA JOLLA PHARMACEUTICAL COMPANY741
AMGEN23.25%132 526
CELGENE CORPORATION19.00%107 551
GILEAD SCIENCES3.00%96 384
REGENERON PHARMACEUTICALS40.54%54 837
VERTEX PHARMACEUTICALS121.49%40 641